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Abstract
Sulforaphane (SFN) and moringin (GMG-ITC) are edible isothiocyanates present as gluco-
sinolate precursors in cruciferous vegetables and in the plantMoringa oleifera respectively,
and recognized for their chemopreventive and medicinal properties. In contrast to the well-
studied SFN, little is known about the molecular pathways targeted by GMG-ITC. We inves-
tigated the ability of GMG-ITC to inhibit essential signaling pathways that are frequently
upregulated in cancer and immune disorders, such as JAK/STAT and NF-κB. We report for
the first time that, similarly to SFN, GMG-ITC in the nanomolar range suppresses IL-3-
induced expression of STAT5 target genes. GMG-ITC, like SFN, does not inhibit STAT5
phosphorylation, suggesting a downstream inhibitory event. Interestingly, treatment with
GMG-ITC or SFN had a limited inhibitory effect on IFNα-induced STAT1 and STAT2 activ-
ity, indicating that both isothiocyanates differentially target JAK/STAT signaling pathways.
Furthermore, we showed that GMG-ITC in the micromolar range is a more potent inhibitor of
TNF-induced NF-κB activity than SFN. Finally, using a cellular system mimicking constitu-
tive active STAT5-induced cell transformation, we demonstrated that SFN can reverse the
survival and growth advantage mediated by oncogenic STAT5 and triggers cell death,
therefore providing experimental evidence of a cancer chemopreventive activity of SFN.
This work thus identified STAT5, and to a lesser extent STAT1/STAT2, as novel targets of
moringin. It also contributes to a better understanding of the biological activities of the die-
tary isothiocyanates GMG-ITC and SFN and further supports their apparent beneficial role
in the prevention of chronic illnesses such as cancer, inflammatory diseases and immune
disorders.
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Introduction
Chronic pathological conditions such as cancer, inflammatory diseases and immune disorders
figure among the leading causes of mortality worldwide [1,2]. Dietary chemoprevention
received increased attention over the past few years as an approach to lower cancer incidence
and mortality [3,4]. The isothiocyanate (ITC) sulforaphane (1-isothiocyanato-4-(methylsulfi-
nyl)-butane, thereafter referred to as SFN) is considered an ideal chemopreventive agent, due
to its abundance in easily accessible cruciferous vegetables, its excellent bioavailability, its abil-
ity to target multiple pathways and its low toxicity [5–9]. Part of the pleiotropic biological
activity of SFN depends on its electrophilic nature, resulting in the direct and/or indirect cova-
lent modification of molecules, including proteins, thus altering their function [10]. Edible
electrophiles such as SFN were shown to exert anti-inflammatory activities for instance
through the activation of the Nrf2-dependent pathway and the inhibition of NF-κB signaling
[10–19].
We also reported recently that SFN inhibits STAT5-mediated transcription [20]. STAT5
(Signal Transducer and Activator of transcription 5) belongs to a family of transcription factors
(STAT1-6) present mainly in an inactive form in the cytoplasm of numerous cell types and
which are activated by phosphorylation in response to specific cytokines, hormones and
growth factors [21–27]. STAT5 is essential for the control of cell proliferation and survival, via
the regulation of genes such as c-Myc, Pim-1, Bcl-x, Osm or Cis [22,28,29]. STAT5 also contrib-
utes to immune cell differentiation and function [27]. Its activity is normally tightly controlled,
and is hence frequently found dysregulated in malignancies and immune disorders [22,27,30–
32]. Notably, STAT5 is commonly constitutively activated in cancer [30,31,33], and is therefore
a target of choice for cancer therapy and prevention [33–37]. A number of small-molecules
inhibitors of the STAT5 signaling pathway have been reported. Most of them, whether natural
or synthetic, target JAK2, a tyrosine kinase responsible for STAT5 phosphorylation [34–46].
Inhibitors targeting STAT5 protein itself and its transcriptional activity have also been
described [20,47–53]. We showed that deacetylase inhibitors and SFN inhibit STAT5 activity
at the transcriptional level, at a step following the binding of STAT5 to DNA [20,53,54]. Other
STAT family members, in particular STAT1 and STAT2, exert essential immune-modulation
functions, in particular in response to infection. They are activated by type I interferons (IFNα/
β) via the JAK1 and TYK2 tyrosine kinases. Phosphorylated STAT1 and STAT2 associate with
IRF9 to form the ISGF3 complex, which translocates into the nucleus and activates the tran-
scription of downstream IFN-stimulated genes or ISGs [55,56]. Alteration of IFN signaling is
linked to immunodeficiencies, auto-immune diseases and cancer [21,27]. Altogether, it has
been recognized that adequate regulation of the JAK/STAT and NF-κB pathways is crucial for
the maintenance of proper immune functions and of controlled cell proliferation and survival,
and hence afford prevention of chronic pathologies such as immune disorders, inflammatory
diseases and cancer.
Beside SFN, another edible ITC from the plantMoringa oleifera, 4-(α-L-rhamnopyranosy-
loxy)-benzyl ITC, also called moringin (thereafter referred to as GMG-ITC), recently attracted
the attention of scientists for its chemopreventive activity. GMG-ITC is produced by myrosi-
nase-catalyzed hydrolysis of glucomoringin (GMG) [57–59].Moringa oleifera is renowned for
its medicinal virtues and nutritional value. All parts of the plant (leaves, seeds, roots, bark,
flowers) are consumed or used in preparations for the treatment of various ailments, including
infections, inflammation, hypertension and diabetes [60]. GMG-ITC has been recently charac-
terized [58] and was shown to exert anti-inflammatory activities both in vitro and in vivo, nota-
bly through the inhibition of the NF-κB pathway [57,61–63]. Thus, like other ITCs and food
electrophiles [10,64], GMG-ITC shares with SFN the ability to inhibit NF-κB signaling.
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Interestingly, GMG-ITC exhibited anti-tumoral activity in a mouse model of multiple mye-
loma, which is considered to be dependent on NF-κB [57]. On the other hand, moringin was
recently described as a potent inducer of apoptosis in a human malignant astrocytoma cell line
[65]. Beside these scarce observations, very little is known about the effect of GMG-ITC on
other signaling pathways, such as JAK/STAT. SFN and GMG-ITC present distinct structures
(Fig 1), raising the possibility that they might possess non-redundant biological activities.
In this study, we investigated the potential inhibitory activity of GMG-ITC on a number of
signaling pathways often deregulated in chronic disorders (STAT5, STAT1, STAT2, NF-κB),
using the well-characterized SFN as a reference compound. We show—to our knowledge for
the first time—that GMG-ITC, similarly to SFN, strongly inhibits STAT5-mediated transcrip-
tion without altering STAT5 activation by phosphorylation. Whereas both ITCs exerted a lim-
ited inhibitory activity toward STAT1/STAT2-mediated transcription, we confirmed that they
are potent inhibitors of NF-κB signaling, GMG-ITC being more efficient than SFN. Altogether,
our data identified STAT5, NF-κB and, to a lesser extent, STAT1/STAT2 as molecular targets
of GMG-ITC and SFN, therefore further supporting the proposed role of these natural ITCs as
valuable dietary chemopreventive agents.
Fig 1. Structure of the natural isothiocyanates sulforaphane (SFN) andmoringin (GMG-ITC).
Sulforaphane (SFN; 1-isothiocyanato-4-(methylsulfinyl)-butane, also called glucoraphanin isothiocyanate or
GRA-ITC) and moringin (4-(α-L-rhamnopyranosyloxy)-benzyl isothiocyanate, also referred to as
glucomoringin isothiocyanate or GMG-ITC) are produced by myrosinase-catalyzed hydrolysis of their
glucosinolate precursors, glucoraphanin (GRA) and glucomoringin (GMG) respectively [59].
doi:10.1371/journal.pone.0157430.g001
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Materials and Methods
Chemicals
Dimethyl sulfoxide (DMSO) and curcumin were purchased from SIGMA (D-2650 and 08511
respectively). R,S-Sulforaphane (SFN) was from LKT Laboratories (S8044). Moringin (GMG-ITC)
was produced by myrosinase-catalyzed hydrolysis of glucomoringin isolated fromMoringa oleifera
Lam. (fam. Moringaceae) seeds and purified by HPLC (>99% purity), as previously described
[57,58]. Compounds were dissolved at 100 mM in DMSO (vehicle). DMSO final concentration
was adjusted in all experiments to 0.01%, with the exception of the gene expression analysis in
TNF-stimulated HeLa cells (0.05% DMSO final) and of theWST-1 assays (0.1% DMSO final).
Cell lines and drug treatments
All cell lines were cultivated at 37°C under 5% CO2 in a humidified incubator. HeLa cells (a kind
gift from Daniela Männel, Institute of Immunology, University of Regensburg, Germany; [66])
were grown in DMEM (Gibco 31966–021) supplemented with 10% heat-inactivated fetal calf
serum (FCS; PAN-Biotech) and penicillin/streptomycin (100 U/mL penicillin, 100 μg/mL strepto-
mycin; PAN-Biotech). The interleukin-3 (IL-3)-dependent mouse pro-B cell line Ba/F3 (a kind
gift from Jacqueline Marvel, International Center for Infectiology Research, Lyon, France; [67])
was grown in RPMI 1640 (PAN-Biotech P04-16500) supplemented with 10% heat-inactivated
FCS, penicillin/streptomycin and 2 ng/mL rmIL-3 (ImmunoTools). The Ba/F3-tet-on-16 cell line
(clone D4.1) conditionally expressing FLAG-tagged constitutively active mouse STAT5A-16 has
been described [54]. Non-induced Ba/F3-tet-on-16 cells were grown in RPMI 1640 supplemented
with 10% heat-inactivated FCS, penicillin/streptomycin, 600 μg/mL G418 (SIGMAA-1720),
800 μg/mL hygromycin B (PAN-Biotech) and 2 ng/mL IL-3. Induction of STAT5A-16 expres-
sion was performed by growing IL-3-withdrawn Ba/F3-tet-on-16 cells in RPMI 1640 supple-
mented with 10% heat-inactivated FCS, penicillin/streptomycin and either 1 μg/mL (first 24
hours) or 100 ng/mL (following 8–11 days) doxycycline (SIGMAD-9891). To achieve a constant
concentration of doxycycline over time, given its half-life of 24 hours, fresh doxycycline was added
daily to the culture at 50 ng/mL, or provided at 100 ng/mL when medium was changed. Treatment
of Ba/F3-tet-on-16 cells with SFN was initiated at the same time as doxycycline. Considering its
expected instability in culture medium, SFN was added fresh daily. For Western Blot analysis,
induced Ba/F3-cells were harvested ~4 hours after the daily addition of doxycycline and SFN.
For drug treatments in RT-qPCR and Western blot assays, HeLa and Ba/F3 cells were incu-
bated with 0.4–10 μM SFN or GMG-ITC, 10–50 μM curcumin, or with 0.01–0.05% DMSO
(vehicle), as indicated, for 30 minutes prior to cytokine stimulation. DMSO was adjusted to
either 0.01% or 0.05% final, as specified, in all conditions. IFNα stimulation of HeLa cells was
performed by incubating cells with 3 ng/mL rhIFNα2a (ImmunoTools) for either 30 minutes
(Western blot analysis of STAT1 and STAT2 phosphorylation) or 4 hours (gene expression
analysis by RT-qPCR). TNF stimulation of HeLa cells was carried out for 1 hour in the pres-
ence of 30 ng/mL TNF (a kind gift from Daniela Männel, Institute of Immunology, University
of Regensburg, Germany). For IL-3 stimulation of Ba/F3 cells, cells were washed twice in RPMI
1640 and rested in RPMI 1640 supplemented with 10% heat-inactivated FCS and penicillin/
streptomycin for 6 hours before addition of 5 ng/mL IL-3 for either 5 minutes (Western blot
analysis of STAT5 phosphorylation) or 30 minutes (gene expression analysis by RT-qPCR).
Gene expression analysis by quantitative RT-PCR
Following cell harvest, Ba/F3 and HeLa cells were lysed in iScript RT-qPCR sample preparation
reagent (170–8899, Bio-Rad Laboratories) at a concentration of 4 x 105 and 1 x 105 cells/mL
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respectively, and 1 μL was used for cDNA synthesis using iScript cDNA Synthesis kit (170–
8891, Bio-Rad Laboratories) following the manufacturer's instructions. Quantitative PCR was
performed on a RotorGene Q (Qiagen) as previously described [54], using 0.4 μL (Ba/F3) or
0.8 μL (HeLa) cDNA template per reaction. Data were normalized to either mouse S9 ribo-
somal mRNA (Ba/F3) or human Lamin A/C (LMNA) mRNA (HeLa), and expressed as relative
mRNA levels, like previously reported [20,29,46,53,54,68,69]. Mouse- and human-specific
quantitative PCR primers have been described [53,54,69]. Data are mean ± SD of the quantita-
tive PCR performed in either duplicate or triplicate and are representative of at least three inde-
pendent experiments. Raw data (CT values) are available in the S1 File.
Cytotoxicity assays
WST-1 assays (11 644 807 001, Roche) were performed to measure changes in mitochondrial
dehydrogenase activity as previously described [20,46], on 0.75 x 105 IL-3-growing Ba/F3 cells
and 0.6 x 104 HeLa cells pre-treated 30 minutes with 0.1–100 μM SFN, 0.02–20 μMGMG-ITC,
or with 0.1% DMSO (vehicle). DMSO concentration was adjusted to 0.1% in all conditions.
Duration of incubation with theWST-1 reagent was 2 hours for Ba/F3 cells and 4 hours for HeLa
cells, to be comparable to the duration of drug treatment in the gene expression analysis experi-
ments. Data are expressed as a percentage of cytotoxicity relative to vehicle. EachWST-1 assay
was performed in triplicate and repeated at least three times for each cell line. Results of one rep-
resentative experiment are shown. Raw data (OD values 450/620 nm) are available in the S1 File.
Cell viability assays
The number of living and dead cells was evaluated by Trypan Blue exclusion following SFN or
GMG-ITC treatment, as previously described [20,46]. Viable cell density (number of living
cells/mL) reflects cell proliferation and survival. Cell death is expressed as the percentage of
dead cells. Data shown are representative of at least three independent experiments.
Protein analysis by Western blot
Whole-cell Brij protein lysis and Western-blot analyses were performed as described [46,54].
Antibodies used for the detection of the respective proteins and their dilutions were: FLAG
(M2, SIGMA F-1804; mouse monoclonal; 1:500), pSTAT1 (sc-135648, Santa-Cruz Biotechnol-
ogy; rabbit polyclonal; 1:1000), pSTAT2 (sc-21689-R, Santa-Cruz Biotechnology; rabbit poly-
clonal; 1:1000), STAT1 (C-terminus, S21120, BD Transduction Laboratories; mouse
monoclonal; 1:1000), STAT2 (C-20, sc-476, Santa-Cruz Biotechnology; rabbit polyclonal;
1:1000), pSTAT5 (#9351, Cell Signaling Technology; rabbit polyclonal; 1:1000), STAT5A (L-
20, sc-1081, Santa-Cruz Biotechnology; rabbit polyclonal; 1:1000), STAT5A+B (C-17, sc-835,
Santa-Cruz Biotechnology; rabbit polyclonal; 1:1000), α-tubulin (DM1A, sc-32293, Santa-Cruz
Biotechnology; mouse monoclonal; 1:200), Anti-Rabbit IgG-Peroxidase (SIGMA A-0545;
1:10,000), Anti-Mouse IgG-Peroxidase (SIGMA A-8924; 1:10,000). Apparent molecular weight
of detected proteins was as predicted by the antibody manufacturers. Immunoblots shown are
representative of at least two independent experiments. Uncropped original blots are available
in the S1 File.
Results
Moringin inhibits IL-3-mediated expression of STAT5 target genes
Ba/F3 are IL-3-dependent mouse pro-B cells commonly used to study STAT5 signaling
[20,29,53,54,67]. We showed before that treatment of Ba/F3 cells with the ITC sulforaphane
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(SFN) inhibits IL-3-induced expression of STAT5 target genes [20]. To investigate the potential
inhibitory activity of moringin (GMG-ITC) on STAT5 activity, Ba/F3 cells were treated for 30
minutes with 0.4–10 μM SFN or GMG-ITC, followed by stimulation with IL-3 for 30 minutes. In
agreement with our reported data [20], expression of the STAT5 target genes Cis,Osm and c-
Myc was inhibited by SFN in a dose-dependent manner, while expression of the housekeeping
gene 36b4 remained unaffected (Fig 2A). Interestingly, expression of Cis, Osm and c-Myc was
similarly inhibited by GMG-ITC in a dose-dependent manner (Fig 2A). In both cases, significant
inhibition was already observed at 0.4 μM ITC (15–30% inhibition depending on the target
gene). The inhibition level on STAT5 target gene expression in the presence of GMG-ITC and
SFN was comparable at 0.4 and 2 μM, while inhibition in the presence of 10 μMGMG-ITC was
slightly stronger than that observed with the same concentration of SFN (100% vs. 77–93%
respectively) (Fig 2A). Cells were subjected to trypan blue exclusion assay after 3 hours and 21
hours of ITC treatment to follow ITC-induced cell viability. As previously observed [20], only
treatment with higher concentrations (10 μM) of SFN led to growth inhibition and partial (34%)
cell death after 21 hours (Fig 2B). In comparison, GMG-ITC significantly inhibited growth at a
concentration of 2 μM after 21 hours of treatment (Fig 2B). Moreover, 10 μMGMG-ITC induced
43% cell death already after 3 hours treatment and 100% cell death at 21 hours (Fig 2B). There-
fore, while both SFN and GMG-ITC exert a similar inhibitory activity toward IL-3-mediated
expression of STAT5 target genes, GMG-ITC appears to exhibit a higher cytotoxicity than SFN
on stimulated Ba/F3 cells. This was confirmed by using aWST-1 assay, measuring changes in the
metabolic activity of Ba/F3 cells upon treatment with 0.1–100 μM SFN or with 0.02–20 μM
GMG-ITC (Fig 2C). Low (20%) cytotoxicity was reached following 2.5 hours treatment with
10 μM SFN or 2 μMGMG-ITC. However, toxicity increased to 60% in Ba/F3 cells treated with
100 μM SFN or 20 μMGMG-ITC (Fig 2C). Together with the massive cell death associated with
prolonged treatment of Ba/F3 cells with 10 μMGMG-ITC, these data indicate that GMG-ITC is
toxic for Ba/F3 cells at concentrations above 2 μM.
Inhibition of STAT5 target gene expression by moringin occurs
downstream of STAT5 phosphorylation
We showed before that SFN inhibits expression of STAT5 target genes without interfering with
STAT5 activation by phosphorylation [20]. We therefore investigated whether treatment of
Ba/F3 cells with GMG-ITC, at a concentration impairing induction of STAT5 target gene
expression without causing toxicity (2 μM), had an effect on STAT5 phosphorylation. Ba/F3
cells were pre-treated 30 minutes with 10 μM SFN or 2 μMGMG-ITC prior to IL-3 stimula-
tion. STAT5 phosphorylation was evaluated by Western blot using antibodies specific for phos-
pho-STAT5 (pSTAT5). STAT5 protein levels were verified using antibodies recognizing
STAT5A and STAT5B proteins (STAT5). Equal protein loading was confirmed by probing the
blot with antibodies directed against α-tubulin. As formerly reported [20], SFN treatment did
not alter IL-3-induced STAT5 phosphorylation (Fig 2D). Similarly, treatment with GMG-ITC
had neither an apparent effect on the level of STAT5 phosphorylation, nor on its protein level
(Fig 2D). These observations suggest that GMG-ITC inhibits STAT5 activity at a step down-
stream of STAT5 activation, as previously proposed for SFN [20].
Moringin and sulforaphane inhibit IFNα-mediated induction of interferon-
stimulated genes without altering STAT1 and STAT2 phosphorylation
The finding that SFN and GMG-ITC both inhibit STAT5-mediated transcription raises the
question of their effect on the activity of other STAT family members. SFN was reported to
inhibit IL-6-induced as well as constitutive STAT3 activity in a number of cancer cell lines
Moringin Inhibits JAK/STAT and NF-κB Signaling
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Fig 2. SFN and GMG-ITC inhibit IL-3-mediated induction of STAT5 target genes in a dose-dependent manner in
Ba/F3 cells. (A) Rested Ba/F3 cells were pre-treated 30 minutes with 0.01% DMSO (vehicle) or with 0.4, 2 and 10 μM
SFN or GMG-ITC, and further stimulated 30 minutes with IL-3. Expression of STAT5 target genes (Cis,Osm, c-Myc)
and of the housekeeping gene 36b4was analyzed by quantitative RT-PCR. One-way ANOVA with Dunnett’s post test
was used to assess differences between isothiocyanate-treated conditions vs. the vehicle-treated IL-3-stimulated
control; *P<0.05, **P<0.01, ***P<0.001. (B) Living and dead cells from experiment shown in panel (A) were
quantified by trypan blue exclusion 3 hours and 21 hours after beginning of isothiocyanate treatment. Data are
Moringin Inhibits JAK/STAT and NF-κB Signaling
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[70–72]. One publication described the ability of SFN to inhibit interferon (IFN)γ-mediated
STAT1 activation [73]. To the best of our knowledge, nothing is known about the effect of SFN
and GMG-ITC on IFNα signaling. Upon stimulation with IFNα, STAT1 and STAT2 are phos-
phorylated and associate with IRF9 to form the so-called ISGF3 complex. In turn, ISGF3
activates expression of interferon-stimulated genes. To investigate the effect of SFN and
GMG-ITC on STAT1/STAT2-mediated transcription, HeLa cells were pre-treated 30 minutes
with 0.4–10 μM SFN or GMG-ITC and stimulated with IFNα2a for 4 hours. Expression of the
interferon-stimulated genes (ISGs) G1P3, ISG15, STAT1 and IRF9 and of the IFN-independent
genes c-Myc and S9 was analysed by RT-qPCR (Fig 3A). At the concentrations of 0.4 and
2 μM, SFN and GMG-ITC did not inhibit IFNα-induced expression of ISGs. At 10 μM how-
ever, ISG induction was strongly inhibited by GMG-ITC (80–100% inhibition) and partially
inhibited by SFN (11–75% inhibition). Induction of the four ISGs investigated was differen-
tially affected by ITC treatment, IRF9 being the least affected (11% and 80% inhibition by
10 μM SFN and GMG-ITC respectively) and G1P3 being more strongly inhibited (75% and
100% inhibition by 10 μM SFN and GMG-ITC respectively). Interestingly, basal expression of
c-Myc remained unaffected upon treatment with up to 10 μM SFN or GMG-ITC (Fig 3A), indi-
cating that both ITCs inhibit STAT5-induced (Fig 2A) but not basal c-Myc transcription.
Expression of the housekeeping gene S9 was comparable in all conditions (Fig 3A).
Cellular toxicity exerted by SFN and GMG-ITC on HeLa cells was assessed as before follow-
ing 4.5 hours ITC treatment. Changes in metabolic activity were comparable as those observed
in Ba/F3 cells, with low (20%) cytotoxicity in the presence of 10 μM SFN or 2 μMGMG-ITC
and increased (60%) cytotoxicity at 100 μM SFN or 20 μMGMG-ITC (Fig 3B). Therefore, sim-
ilarly to its effect on Ba/F3 cells, GMG-ITC exerts a stronger cytotoxicity on HeLa cells than
SFN. These data also suggest that SFN-mediated inhibition of STAT1/STAT2-induced tran-
scription observed at 10 μM occurs independently of cytotoxicity, while GMG-ITC-mediated
inhibition at 10 μMmight result, at least in part, from cell toxicity.
We next investigated whether treatment with SFN or GMG-ITC had an effect on STAT1
and/or STAT2 phosphorylation, using non-toxic ITC concentrations. HeLa cells were pre-
treated for 30 minutes with 10 μM SFN or 2 μMGMG-ITC and stimulated with IFNα2a for 30
minutes. STAT1 and STAT2 phosphorylation was evaluated by Western blot using phospho-
specific antibodies. Treatment of IFNα-stimulated HeLa cells with SFN or GMG-ITC had no
major effect on STAT1 and STAT2 phosphorylation and did not affect their respective protein
levels (Fig 3C). Given that 10 μM SFN was sufficient to inhibit IFNα-induced ISG expression,
these data indicate that SFN-mediated repression of IFNα signaling does not involve the inhi-
bition of STAT1 or STAT2 phosphorylation. It therefore suggests a mechanism of inhibition
similar to that mediated by SFN on STAT5 signaling, likely involving a downstream effect. The
absence of effect of GMG-ITC on STAT1/STAT2 phosphorylation also suggests a similar
mechanism. However, since 2 μMGMG-ITC had no effect on IFNα-induced ISG expression,
we cannot definitely conclude that it is the case.
expressed as living cell density (left graph) and as percentage of dead cells (right graph). (C)GMG-ITC exhibits a
higher toxicity than SFN in Ba/F3 cells. Ba/F3 cells were pre-treated 30 minutes with 0.1, 1, 10 and 100 μMSFN or with
0.02, 0.2, 2 and 20 μMGMG-ITC (0.1% DMSO in all conditions) prior to addition of theWST-1 reagent. Assay was
conducted for 2 hours, as described in Materials and Methods, and cell toxicity was expressed as a percentage of the
vehicle control. Note that the x-axis indicates relative isothiocyanate (ITC) concentrations, with 1 corresponding to
0.1 μMSFN and 0.02 μMGMG-ITC. (D) Like SFN, GMG-ITC does not affect IL-3-induced phosphorylation of STAT5.
Rested Ba/F3 cells were pre-treated 30 minutes with 10 μMSFN, 2 μMGMG-ITC or 0.01%DMSO as vehicle control
(-) and further stimulated 5 minutes with IL-3. Whole-cell protein lysates were analysed byWestern blot using
antibodies directed against phosphorylated STAT5 (pSTAT5), STAT5A+B (STAT5) and α-tubulin as a loading control.
ITC, isothiocyanate.
doi:10.1371/journal.pone.0157430.g002
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Fig 3. SFN and GMG-ITC inhibit IFNα-mediated induction of STAT1/STAT2 target genes in a dose-
dependent manner in HeLa cells. (A) HeLa cells were treated 30 minutes with 0.01% DMSO (vehicle) or with
0.4, 2 and 10 μMSFN or GMG-ITC, and further stimulated with IFNα2a for 4 hours. Expression of interferon-
stimulated genes (G1P3, ISG15, STAT1, IRF9), of an interferon-independent gene (c-Myc) and of the
housekeeping gene S9 was analyzed by quantitative RT-PCR. One-way ANOVA with Dunnett’s post test was
Moringin Inhibits JAK/STAT and NF-κB Signaling
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Moringin and sulforaphane strongly inhibit TNF-induced expression of
NF-κB target genes
A number of independent reports indicate that both SFN and GMG-ITC inhibit NF-κB signal-
ing in vitro and in vivo [13,15,16,18,57,61,62,74]. One study compared the ability of SFN and
GMG-ITC to inhibit constitutive NF-κB activity in cancer cell lines [57]. However, the respec-
tive inhibitory activity of SFN and GMG-ITC on a model of TNF-induced NF-κB activation
has not been studied. We compared the potency of SFN and GMG-ITC to inhibit NF-κB activ-
ity, in parallel to curcumin, another natural product and acknowledged NF-κB inhibitor [75].
HeLa cells were pre-treated 30 minutes with 0.4–10 μM ITCs or with 10–50 μM curcumin and
further stimulated with TNF for 1 hour. Expression of NF-κB target genes (IL-8, IL-6) and of
the housekeeping gene S9 was assessed by RT-qPCR (Fig 4). TNF-induced expression of IL-8
and IL-6 was inhibited by all three compounds in a dose-dependent manner. Significant inhibi-
tion by SFN and GMG-ITC was detected already at 2 μM and was stronger in the presence of
GMG-ITC (~50% inhibition compared to ~28% with SFN). Complete inhibition of NF-κB tar-
get gene expression was observed at 10 μM SFN or GMG-ITC, while inhibition only reached
8–24% (depending on the target gene) upon treatment with the same concentration of curcu-
min. Expression of the control gene S9 remained mostly unchanged in all conditions. Together,
these experiments reveal that both SFN and GMG-ITC inhibit NF-κB signaling with a greater
potency than that mediated by the well-characterized NF-κB inhibitor curcumin. Beside,
GMG-ITC appears to be more potent at 2 μM than SFN in inhibiting TNF-induced gene
expression.
Sulforaphane acts as a chemopreventive agent in a model of
STAT5-induced cell transformation
The ability of natural compounds such as the ITCs SFN and GMG-ITC to inhibit multiple sig-
naling pathways controlling cell proliferation, cell survival, immune modulation and inflam-
mation, make them attractive agents in particular for cancer prevention. To assess the
chemopreventive activity of natural compounds, we developed a cellular model of STAT5-in-
duced oncogenic transformation, so-called Ba/F3-tet-on-16 (Fig 5A). Ba/F3-tet-on-16 cells
express a constitutively active mutant of STAT5 (STAT5A-16) upon treatment with the tetra-
cycline analog doxycycline [54,76]. Upon expression of STAT5A-16, Ba/F3 cells—which are
normally dependent on IL-3 for survival and growth—acquire the ability to survive in the
absence of IL-3, eventually grow in an IL-3-independent manner and are highly tumorigenic in
vivo [54,68,76,77]. Ba/F3-tet-on-16 cells thus represent an ideal experimental system to inves-
tigate the potential chemopreventive activity of natural compounds. SFN was chosen for these
experiments due to its low toxicity in long-term cultures. Expression of STAT5A-16 was
induced by doxycycline treatment of Ba/F3-tet-on-16 cells, in the absence or presence of IL-3
and of increasing concentrations of SFN (0, 1 and 2 μM). SFN treatment of non-induced cells
used to assess differences between isothiocyanate-treated conditions vs. the vehicle-treated IFNα2a-stimulated
control; *P<0.05, **P<0.01, ***P<0.001. (B)GMG-ITC exhibits a higher toxicity than SFN in HeLa cells. HeLa
cells were pre-treated 30 minutes with 0.1, 1, 10 and 100 μMSFN or with 0.02, 0.2, 2 and 20 μMGMG-ITC (0.1%
DMSO in all conditions) prior to addition of theWST-1 reagent. Assay was conducted for 4 hours, as described in
Materials and Methods, and toxicity was normalized to the DMSO vehicle control. The x-axis indicates relative
isothiocyanate (ITC) concentrations, with 1 corresponding to 0.1 μMSFN and 0.02 μMGMG-ITC. (C) SFN and
GMG-ITC do not alter IFNα-induced phosphorylation of STAT1 and STAT2. HeLa cells were pre-treated 30
minutes with 10 μMSFN, 2 μMGMG-ITC or 0.01% DMSO as vehicle control (-) and further stimulated 30 minutes
with IFNα2a. Whole-cell protein lysates were analysed byWestern blot using antibodies directed against
pSTAT1, pSTAT2, STAT1, STAT2 and α-tubulin (loading control). ITC, isothiocyanate.
doi:10.1371/journal.pone.0157430.g003
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Fig 4. SFN and GMG-ITC inhibit TNF-mediated induction of NF-κB target genes in a dose-dependent
manner in HeLa cells. HeLa cells were pre-treated 30 minutes with 0.05% DMSO (vehicle), with 0.4, 2 and
10 μMSFN or GMG-ITC or with 10 and 50 μM of the natural NF-κB inhibitor curcumin. Following drug
treatment, cells were stimulated with TNF for 1 hour, and expression of the NF-κB target genes (IL-6, IL-8)
and of the housekeeping gene S9 was analyzed by quantitative RT-PCR. One-way ANOVA with Dunnett’s
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grown in the presence of IL-3 (non-transformed control cells) resulted in a dose-dependent
cell growth inhibition but did not induce cell death (S1 Fig and Fig 5B). As predicted, non-
induced cells withdrawn from IL-3 died within the first two days (S1 Fig and Fig 5B). Seventy
to 80% of Ba/F3-tet-on-16 cells expressing constitutive active STAT5A-16 survived in IL-
3-free culture and started growing after 5–6 days in culture (S1 Fig and Fig 5B). Interestingly,
induced cells grown in the presence of SFN showed reduced survival and proliferation in a
dose-dependent manner (S1 Fig and Fig 5B). Treatment of STAT5A-16-transformed cells
with 2 μM SFN resulted in 100% cell death after 6–11 days in culture (S1 Fig and Fig 5B).
These data show that SFN is able to reverse the survival and growth advantage exerted by
STAT5A-16 and to induce the death of transformed cells.
Doxycycline-dependent expression and phosphorylation of FLAG-tagged STAT5A-16 was
verified by Western blot using FLAG-, STAT5- and phospho-STAT5-specific antibodies (Fig
5C). STAT5A-16 transgene was constantly expressed over the course of the experiment
(FLAG and STAT5 blots). STAT5A-16 phosphorylation level was equal in untreated induced
cells. However, the level of phosphorylated STAT5 decreased at days 5 and 8 in cells treated
with 2 μM SFN (Fig 5C). Whether this reduction is a consequence of the high cell death associ-
ated with these samples (65% and 83% cell death at day 5 and day 8 respectively) or reflects a
downregulation of STAT5A-16 activity by SFN remains to be shown.
Discussion
This study aimed to analyse and compare the inhibitory activities of two natural ITCs, sulfo-
raphane (SFN) and moringin (GMG-ITC). We focused on a number of signaling pathways
essential for the control of cell proliferation, apoptosis, immune response and inflammation
and known to be dysregulated in various chronic diseases. Gene expression analyses revealed
that SFN and GMG-ITC differentially affected the investigated signaling pathways. We found
that both SFN and GMG-ITC inhibit IL-3-induced STAT5 signaling at concentrations as low
as 0.4 μM. This is to our knowledge the first demonstration of an inhibitory effect of GMG-ITC
on STAT5-mediated transcription. We also showed for the first time that both ITCs inhibit to
some extent IFNα-induced STAT1 and STAT2 activity, although the effective concentration
was 25-times higher (10 μM) than that required for inhibition of STAT5 activity. In both cases,
inhibition of JAK/STAT signaling did not take place at the level of STAT protein phosphoryla-
tion, suggesting a downstream inhibitory event. Interestingly, SFN and GMG-ITC specifically
impaired STAT5-dependent (Ba/F3) but not basal (HeLa) c-Myc expression, highlighting the
specificity of action of these ITCs. Furthermore, SFN and GMG-ITC inhibit TNF-induced NF-
κB signaling, thus supporting previous studies performed in other experimental systems
[57,61–63]. Inhibition of NF-κB activation by ITCs was detectable at concentrations of 2 μM.
SFN and GMG-ITC are thus more potent inhibitors of NF-κB than the acknowledged inhibitor
curcumin, which required a concentration of at least 10 μM to mediate a comparable inhibitory
effect on NF-κB target gene expression. While SFN and GMG-ITC were equally potent inhibi-
tors of STAT5 signaling, GMG-ITC appeared to be more effective in the inhibition of STAT1/
STAT2 and of NF-κB than SFN. On the other hand, GMG-ITC treatment was more cytotoxic
than SFN treatment for both Ba/F3 and HeLa cells. Therefore, one cannot exclude that the
stronger inhibitory activity observed upon treatment with 10 μMGMG-ITC is related to its
cytotoxicity. In particular, this might be the case for the inhibition of IFNα-induced STAT1/
STAT2/IRF9 signaling which was only evident at higher ITC concentrations. Interestingly, the
post test was used to assess differences between drug-treated conditions vs. the vehicle-treated TNF-
stimulated control; *P<0.05, ***P<0.001.
doi:10.1371/journal.pone.0157430.g004
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Fig 5. SFN treatment impairs STAT5A-1*6-mediated survival and growth of Ba/F3 cells. (A) Schematic
representation of the growth and survival behavior of non-induced and doxycycline (Dox)-induced Ba/F3-tet-on-
1*6 in the presence or absence of IL-3. Non-induced Ba/F3-tet-on-1*6 cells are IL-3-dependent (-Dox, +IL-3), like
parental Ba/F3 cells. IL-3-growing cells express active endogenous STAT5 (WTON). Upon IL-3 withdrawal,
endogenous STAT5 activity is turned off (WTOFF) and non-induced Ba/F3-tet-on-1*6 cells rapidly undergo
apoptosis (-Dox, -IL-3). Treatment of Ba/F3-tet-on-1*6 cells with doxycycline results in the expression of the
constitutively active STAT5A-1*6 mutant (1*6ON) [76], allowing cells to survive and eventually grow in the
absence of IL-3 (+Dox, -IL-3). In these conditions, endogenous wild-type STAT5 is inactive (WTOFF). (B, C) Non-
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IFN-regulated gene IRF9 showed a drastic difference in sensitivity to SFN and GMG-ITC treat-
ment, being only marginally affected upon treatment with 10 μM SFN and strongly inhibited
by GMG-ITC at the same concentration. Since IRF9 is an essential cofactor of the ISGF3 com-
plex, a stronger inhibition of IRF9 by GMG-ITC might also explain the overall stronger inhibi-
tion of ISG expression by GMG-ITC.
The observation that STAT5 target gene expression is similarly inhibited by SFN and
GMG-ITC treatment may suggest a similar inhibitory mechanism. This possibility is supported
by the observation that neither SFN nor GMG-ITC treatment interfere with STAT5 phos-
phorylation. We showed before that SFN treatment does not affect STAT5 activation (phos-
phorylation), nor its binding to DNA, and only marginally interferes with STAT5-mediated
recruitment of RNA polymerase II [20]. Furthermore, SFN treatment had no apparent effect
on histone acetylation levels in Ba/F3 cells [20], suggesting that it does not act as a histone dea-
cetylase inhibitor [78,79]. Our data therefore supported a model in which SFN targets STAT5
transcriptional activity at a step following binding of activated STAT5 to DNA and recruitment
of the transcriptional machinery. Whether inhibition by GMG-ITC involves a similar mecha-
nism remains to be shown.
The finding that SFN and GMG-ITC treatment does not alter STAT1 and STAT2 phos-
phorylation similarly suggest that inhibition of IFN-stimulated gene expression takes place at
the transcriptional level. This proposition is further supported by the fact that expression of the
ISGs investigated (G1P3, ISG15, STAT1 and IRF9) was differentially affected upon SFN and
GMG-ITC treatment, in favor of a promoter-specific regulation. Further investigations will be
necessary to address the level of inhibition by these natural ITCs. It should be noted that, in
contrast to STAT1/2/5 proteins, constitutive and IL-6-induced STAT3 phosphorylation was
shown to be reduced upon treatment by SFN in a number of cancer cell lines [70–72], thus
revealing multiple modes of regulation of STAT proteins by ITCs.
In contrast to STAT5 target gene expression, which was equally affected by SFN and
GMG-ITC in Ba/F3 cells, TNF-induced NF-κB-mediated transcription in HeLa cells was more
strongly inhibited by GMG-ITC than by SFN. Similarly, GMG-ITC was more effective than
SFN in inhibiting NF-κB activity in macrophages and multiple myeloma cells [57]. This differ-
ence in activity might reflect a distinct mode of action or a differential ability of GMG-ITC and
SFN to interact with common target proteins, possibly due to differences in their chemical
structure (Fig 1). While little is known about the mechanism of inhibition of NF-κB signaling
by GMG-ITC [57,61–63,80], SFN appears to directly and indirectly inhibit NF-κB signaling at
multiple levels, targeting both upstream and downstream components of the pathway [11–19].
The molecular mechanism by which SFN and GMG-ITC inhibit STAT and NF-κB signaling
pathways remains to be uncovered. ITCs are electrophiles known for their ability to react with
thiols [10]. SFN was shown to react with free sulfhydryl groups of cysteines in proteins and
modify their function [8,16,81,82]. Therefore, it is likely that SFN and GMG-ITC react with
induced and Dox-induced Ba/F3-tet-on-1*6 cells were grown in the absence or presence of IL-3, and were treated
with 2 μMSFN or left untreated, as indicated, for up to 11 days. Living and dead cells were counted every day by
trypan blue exclusion (B) and were harvested for Western blot analysis (C). The ‘no Dox, no IL-3’ control cells
shown in lane 2 of theWestern blot were harvested after 6 hours of IL-3 withdrawal. The FLAG-specific antibody
recognizes flag-tagged STAT5A-1*6 in Dox-induced cells; pSTAT5 detects phosphorylated STAT5 (endogenous
WT in IL-3-growing non-induced cells and STAT5A-1*6 in Dox-induced cells); STAT5A-specific antibodies
(STAT5A and STAT5A+B) recognize both endogenousWT STAT5A and induced STAT5A-1*6; STAT5B-specific
antibodies (STAT5A+B) recognize endogenous WT STAT5B proteins; α-tubulin was used as a loading control.
Western blot analysis showed that STAT5A-1*6 was overexpressed compared to endogenous STAT5A and
STAT5B upon treatment with doxycycline. Moreover, expression of STAT5A-1*6 remained constant over time
regardless of the presence of SFN. By contrast, STAT5A-1*6 phosphorylation decreased after 5 days of treatment
with 2 μMSFN.
doi:10.1371/journal.pone.0157430.g005
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cysteine residues within STAT proteins or with a cofactor of STAT-mediated transcription, as
well as with components of the NF-κB signaling pathway. On the other hand, SFN reacts with
intracellular glutathione (GSH), which contributes to the rapid cellular uptake and accumula-
tion of SFN and to a concomitant drop in endogenous GSH levels [9]. A drop in GSH might
trigger S-glutathionylation of cysteines within STAT and/or NF-κB transcription factors,
thereby inhibiting their activity, as demonstrated for other electrophilic natural compounds
[83–86]. Although thiol- and redox-dependent mechanisms of inhibition of NF-κB activity by
SFN have been reported [16–19], further investigations will be necessary to determine their
contribution in SFN- and GMG-ITC-mediated inhibition of STAT and NF-κB signaling
pathways.
Natural ITCs such as SFN and GMG-ITC have long been known for their chemopreventive
activities against various pathologies. Using our STAT5-induced cell transformation assay, we
provide strong evidence that SFN can counteract STAT5A-16-driven oncogenesis, by induc-
ing cell death of transformed—but not of healthy—cells. The observation that STAT5A-16
phosphorylation was reduced in SFN-treated cells suggests that inhibition of STAT5 activity
contributes at least in part to SFN-induced cell death. However, given the pleiotropic activities
of SFN, further experiments will be required to identify the critical targets of SFN in Ba/F3 cells
transformed by constitutive active STAT5.
In conclusion, our data indicate that SFN and GMG-ITC are potent inhibitors of STAT5,
NF-κB and, to a lesser extent, STAT1/STAT2 signaling pathways. Given the implication of
these pathways in chronic pathologies such as cancer, inflammatory diseases and immune dis-
orders, the dietary and easily available ITCs SFN and GMG-ITC represent attractive and valu-
able chemopreventive agents.
Supporting Information
S1 Fig. SFN treatment prevents STAT5A-16-mediated survival and growth of Ba/F3 cells
in a dose-dependent manner.Non-induced and Dox-induced Ba/F3-tet-on-16 cells were
grown in the absence or presence of IL-3, and were treated with 0, 1 or 2 μM SFN, as indicated,
for up to 8 days. Living and dead cells were counted every day by trypan blue exclusion. Data
are expressed as percentage of dead cells (% dead cells) and as density of living cells (number of
living cells/mL). To better visualize SFN-induced cell growth inhibition in non-induced cells,
the Y-axis scale of the corresponding graph was expanded (lower left graph).
(EPS)
S1 File. Raw data. RT-qPCR CT values; WST-1 OD values; uncropped Western blots.
(PDF)
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